Revenue from operations grew 10.5% yoy to ₹13,675.4 crore, compared with ₹12,381 crore registered for the same period in Q3 ...

EBITDA declined 4.8% YoY to ₹3,069.4 crore, though EBITDA margin rose by 50 basis points to 13.4% from 12.9% last year.

Dr Lal Pathlabs Ltd EBITDA grew 9.5% YoY to ₹154 crore, though margins contracted slightly to 25.8% from 26.1% last year ...

The board approved the second interim dividend of ₹5 per share amounting to 100% of face value, amounting to ₹6,290 crore.

The industry hopes for more headroom for higher allocations for rural development schemes to pump up sales in smaller towns ...

The company registered a 28% increase in its December quarter’s Asset Under Management (AUM) at ₹3,98,043 Crore.

The currency has been under pressure, thus stabilizing it involves injecting Rs 600 billion into banks through bond purchases ...

Compared to 86.6250 in the previous session and flirting with the record low of 86.6475 hit almost two weeks ago, the 1-month ...

However, despite excellent performance during the quarter, EBITDA margins declined to 6% in Q3FY25, against 7.1% in Q3FY24.

The company’s revenue for the quarter registered an increase of 116% y-o-y to ₹3,457 Crore as compared to ₹1,596 Crore.

Adjusting for these one-time factors, operating revenue of Biocon grew 10% YoY to ₹3,821 crore, with total revenue increasing ...

Revenue increased 15% YoY at ₹1,153.7 crore from ₹1,005.8 crore in Q3 FY24, marking a consistent business growth.